• Fractyl Health appointed Michael Wartell as an independent Class III director effective November 2, 2026; his term expires at the 2027 annual meeting.
• The board expanded from nine to ten members.
• Wartell is president of Bluerose Associates LLC, with experience as an independent director guiding public and private companies through complex situations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fractyl Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876776) on November 12, 2026, and is solely responsible for the information contained therein.